In this review:
This publication summarises an educational meeting presented by Professor Bruce Taylor on Monday
9th March 2020. Professor Taylor reviewed published data on Ocrevus® (ocrelizumab) for the treatment
of multiple sclerosis, and discussed his 10 years of experience with using the drug for patients with
relapsing forms of multiple sclerosis and primary progressive multiple sclerosis in Australia. Also included is a short commentary on Ocrevus and COVID-19, the NZ perspective, provided by Dr Jennifer Pereira on 18th May 2020. The meeting was sponsored by Roche Products (New Zealand) Limited.
Download PDF